Skip to NavigationSkip to content

Insys Therapeutics

Insys Therapeutics founder John Kapoor found guilty of bribing doctors

The founder of opioid drugmaker Insys Therapeutics has been found guilty of bribing doctors in order to persuade them to prescribe the fentanyl-based painkiller Subsys.

A Boston jury found John Kapoor guilty of racketeering conspiracy after the billionaire pharma chief was found to have bribed doctors and defrauded insurance companies, as part of an effort to boost sales of the sublingual fentanyl spray Subsys.

While Subsys had been approved for patients with terminal cancer, the company targeted patients with non-life threatening chronic pain.

Insys Therapeutics names current CFO Andrew Long as company's new CEO

Published on: 17/04/19

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s new CEO.

The opioid drugmaker said the decision had come after Motahari agreed to step down from the position of President and CEO.

The firm, who have faced legal issues over the marketing of their fentanyl based spray Subsys, have seen a series of successions in recent years after CEO Michael Babich was arrested in 2016.

The company were thus keen to emphasise their leadership in the “development, manufacture and commercialization of pharmaceutical cannabinoids.”

Insys Therapeutics names current CFO Andrew Long as company's new CEO

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s new CEO.

The opioid drugmaker said the decision had come after Motahari agreed to step down from the position of President and CEO.

The firm, who have faced legal issues over the marketing of their fentanyl based spray Subsys, have seen a series of successions in recent years after CEO Michael Babich was arrested in 2016.

Insys Therapeutics sees revenue from Subsys at $61-$62 million; shares plunge 21%

Insys Therapeutics Inc (Nasdaq: INSY) stock plunged nearly 21% Monday after the company said sales for its pain drug will be impacted by a decline in demand.

The company forecast first-quarter revenue from Subsys (fentanyl sublingual spray) in the range of $61 million to $62 million saying the figures reflect a decline in demand on the back of lower prescription for the therapy.

The company reported total revenue of $70.77 million for the same period last year.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches